Fundraising FoxCelmatix
New York, US · Founded 2010 · Delaware corporation · 1 known investors
Find your way into Celmatix
Sign up to see every warm intro you have to Celmatix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Celmatix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Celmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.
Founders & leadership
Celmatix was founded in 2010 by Piraye Yurttas Beim.
PY
Piraye Yurttas BeimFounder
Board
SW
Steven WinickBoard director
LT
Laura Towart BandakBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$15.6M disclosed across 4 rounds · 2012–2016
▶$4.8MraisedApr 2016 · 1 investors · BiotechnologyRule 506(b)
▶$4.8MraisedApr 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Laura BandakDirector
- Steven J. WinickDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedSep 2015 · 5 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2015 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Steven J. WinickDirector
- Laura BandakDirector
- Offering amount
- $5.2M
- Amount sold
- $3.8M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJul 2015 · 6 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJul 2015 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Steven WinickDirector
- Laura Towart BandakDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2012 · 10 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2012 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Laura Towart BandakExecutive Officer, Director
- Steven WinickDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Companies working in the same space as Celmatix.
Frequently asked questions
- What does Celmatix do?
- Celmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.
- Who founded Celmatix?
- Celmatix was founded by Piraye Yurttas Beim in 2010.
- Who are Celmatix's investors?
- Celmatix's investors include Lauder Partners.
- How much funding has Celmatix raised?
- Celmatix has disclosed $15.6M raised across 4 rounds.
- Where is Celmatix headquartered?
- Celmatix is headquartered in New York, US.